Medicus Pharma has confirmed the 200-microgram dose of its SkinJect patch for further studies targeting Gorlin syndrome, with FDA approval for a pivotal trial underway. The company is also exploring an out-licence for nodular basal cell carcinoma and highlights a potential partnership opportunity for SkinJect. Additionally, Medicus Pharma is advancing a co-development deal with Pfizer on a CD228-targeted antibody-drug conjugate for melanoma and solid tumors, supported by $2 million in funding. These developments position Medicus Pharma as a precision oncology biotech with several upcoming catalysts including patient recruitment and program advancements.
Jim Cramer highlighted large flex-call option purchases in tech and energy stocks like Bloom Energy and Intel, raising questions about the buyer's identity. Weeks earlier, a House disclosure showed Pelosi's spouse had bought shares and call options i...
Investment firm Multicoin Capital has identified Hyperliquid as one of its largest holdings following a detailed reassessment of the protocol. This decision reflects confidence in Hyperliquid's growth, driven by increased liquidity and developer acti...
Bitcoin is holding steady around $77,300 but faces strong selling pressure between $77,100 and $80,200, making a breakout above $80,000 challenging. The next major resistance is the 365-day moving average near $81,700, a level historically linked to ...
A recent SEC filing reveals that Megacorn Fund LP's Ripple shares increased in value by about 62.4% from an original cost of $229,840 to a fair value of $373,179 by the end of 2025. This gain followed Ripple's $500 million strategic investment round ...
Elon Musk declared that the sun, as a massive free fusion reactor, will eventually provide 100% of humanity's energy, dismissing terrestrial fusion reactors as inefficient. Tesla's energy segment shows strong growth with rising revenue and storage de...
